Most people’s tests of potential treatments for chronic conditions involve haphazard cycling through doses and brands, spotty symptom diaries and no statistical analysis of results. This lack of rigor introduces numerous cognitive biases.
Industrial medicine views random control trials (RCTs) as the gold standard for determining the efficacy of medications. The thinking goes: blinding, controls/placebos and regular reporting produce objectively reliable, generalizable results. Yet critics argue that RCTs, at least the ones that clinicians habitually read in the reprints of medical journal articles shared by drug company reps, […]